These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25286176)

  • 1. Molecular dynamics of CYP2D6 polymorphisms in the absence and presence of a mechanism-based inactivator reveals changes in local flexibility and dominant substrate access channels.
    de Waal PW; Sunden KF; Furge LL
    PLoS One; 2014; 9(10):e108607. PubMed ID: 25286176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted imidazole of 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates cytochrome P450 2D6 by protein adduction.
    Nagy LD; Mocny CS; Diffenderfer LE; Hsi DJ; Butler BF; Arthur EJ; Fletke KJ; Palamanda JR; Nomeir AA; Furge LL
    Drug Metab Dispos; 2011 Jun; 39(6):974-83. PubMed ID: 21422192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
    Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Dynamics Simulations Reveal Structural Differences among Allelic Variants of Membrane-Anchored Cytochrome P450 2D6.
    Fischer A; Don CG; Smieško M
    J Chem Inf Model; 2018 Sep; 58(9):1962-1975. PubMed ID: 30126275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712.
    Glass SM; Martell CM; Oswalt AK; Osorio-Vasquez V; Cho C; Hicks MJ; Mills JM; Fujiwara R; Glista MJ; Kamath SS; Furge LL
    Drug Metab Dispos; 2018 Aug; 46(8):1106-1117. PubMed ID: 29784728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microsecond MD simulations of human CYP2D6 wild-type and five allelic variants reveal mechanistic insights on the function.
    Don CG; Smieško M
    PLoS One; 2018; 13(8):e0202534. PubMed ID: 30133539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations.
    Hendrychová T; Anzenbacherová E; Hudeček J; Skopalík J; Lange R; Hildebrandt P; Otyepka M; Anzenbacher P
    Biochim Biophys Acta; 2011 Jan; 1814(1):58-68. PubMed ID: 20656072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B.
    Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
    Drug Metab Bioanal Lett; 2022; 15(1):51-63. PubMed ID: 35049443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.
    Unwalla RJ; Cross JB; Salaniwal S; Shilling AD; Leung L; Kao J; Humblet C
    J Comput Aided Mol Des; 2010 Mar; 24(3):237-56. PubMed ID: 20361239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tryptophan-75 Is a Low-Energy Channel-Gating Residue that Facilitates Substrate Egress/Access in Cytochrome P450 2D6.
    McCarty KD; Ratliff SA; Furge KA; Furge LL
    Drug Metab Dispos; 2021 Mar; 49(3):179-187. PubMed ID: 33376147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators.
    Livezey M; Nagy LD; Diffenderfer LE; Arthur EJ; Hsi DJ; Holton JM; Furge LL
    Drug Metab Lett; 2012 Mar; 6(1):7-14. PubMed ID: 22372551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6.
    Martiny VY; Carbonell P; Chevillard F; Moroy G; Nicot AB; Vayer P; Villoutreix BO; Miteva MA
    Bioinformatics; 2015 Dec; 31(24):3930-7. PubMed ID: 26315915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of CYP2D6 substrate interactions by computational methods.
    Ito Y; Kondo H; Goldfarb PS; Lewis DF
    J Mol Graph Model; 2008 Feb; 26(6):947-56. PubMed ID: 17764997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
    Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
    Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous Ligand Access Events to Membrane-Bound Cytochrome P450 2D6 Sampled at Atomic Resolution.
    Fischer A; Smieško M
    Sci Rep; 2019 Nov; 9(1):16411. PubMed ID: 31712722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.
    Ford KA; Ryslik G; Sodhi J; Halladay J; Diaz D; Dambach D; Masuda M
    Drug Metab Rev; 2015 Aug; 47(3):291-319. PubMed ID: 26024250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6.
    de Graaf C; Oostenbrink C; Keizers PH; van Vugt-Lussenburg BM; van Waterschoot RA; Tschirret-Guth RA; Commandeur JN; Vermeulen NP
    Curr Drug Metab; 2007 Jan; 8(1):59-77. PubMed ID: 17266524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening.
    Mo SL; Liu WF; Li CG; Zhou ZW; Luo HB; Chew H; Liang J; Zhou SF
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1640-704. PubMed ID: 22039821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Analysis of Physicochemical Factors Driving CYP2D6 Ligand Interaction.
    Olubiyi OO; Olagunju MO; Obisesan AO
    Curr Comput Aided Drug Des; 2017; 13(1):39-47. PubMed ID: 27632988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.